Background: Breast cancer (BC) diagnosis may have a high emotional impact in patients. Health-related quality of life (HRQL) can be impaired by the psychological impact of the diagnosis, by choices having to be made about treatment and by treatments themselves. Methods: Cross-sectional analysis of HRQL in BC women from the Epi-GEICAM casecontrol study carried out in 23 Spanish hospitals. Women fulfilled a questionnaire about sociodemographic and lifestyle factors, HRQL (SF-36), mental health (GHQ-28) and social support (Duke-UNC). Spanish population norm-based scores were calculated for the SF-36 scales. Physical (PSS) and mental (MSS) summary scores 5 points under the norm were considered suboptimal. Psychological distress (PD) was defined as GHQ-28 >5. Factors associated with PD and suboptimal PSS were identified by multivariable mixed logistic regression models. Results: Among 1017 cases, 896 had complete SF-36 and GHQ-28. Median time since diagnosis was 77 days, 82% had been operated on, and 41% were on radiation/chemotherapy. Prevalence of PD was 54.4% (95% CI: 51.1-57.6). PD increased with TNM stage (p ¼ 0.03). Other factors associated with PD were chemotherapy (OR ¼ 1.7; 95% CI: 1.2-2.6), low social support (OR ¼ 2.0; 95%CI: 1.2-3.5) and low education (OR ¼ 2.1; 95% CI: 1.2-3.8). SF-36 scores are described in the table. Factors related to suboptimal PSS were surgery (OR ¼ 3.2, 95% CI: 2.0-5.1), low education (OR ¼ 1.9, 95% CI: 1.1-3.6) and number of comorbidities (OR ¼ 1.3, 95% CI: 1.0-1.5). No differences in PD or PSS were observed according to BC subtype. Conclusions: PD is very frequent during the initial stages of BC diagnosis and treatment. Advanced disease stage, lack of social support and low education are strong determinants of PD. The highest impact in HRQL was observed in the role-physical domain. PD and low PSS are interrelated and both are more frequent in patients with low education.
Background: Breast cancer (BC) diagnosis may have a high emotional impact in patients. Health-related quality of life (HRQL) can be impaired by the psychological impact of the diagnosis, by choices having to be made about treatment and by treatments themselves. Methods: Cross-sectional analysis of HRQL in BC women from the Epi-GEICAM casecontrol study carried out in 23 Spanish hospitals. Women fulfilled a questionnaire about sociodemographic and lifestyle factors, HRQL (SF-36), mental health (GHQ-28) and social support (Duke-UNC). Spanish population norm-based scores were calculated for the SF-36 scales. Physical (PSS) and mental (MSS) summary scores 5 points under the norm were considered suboptimal. Psychological distress (PD) was defined as GHQ-28 >5. Factors associated with PD and suboptimal PSS were identified by multivariable mixed logistic regression models. Results: Among 1017 cases, 896 had complete SF-36 and GHQ-28. Median time since diagnosis was 77 days, 82% had been operated on, and 41% were on radiation/chemotherapy. Prevalence of PD was 54.4% (95% CI: 51.1-57.6). PD increased with TNM stage (p ¼ 0.03). Other factors associated with PD were chemotherapy (OR ¼ 1.7; 95% CI: 1.2-2.6), low social support (OR ¼ 2.0; 95%CI: 1.2-3.5) and low education (OR ¼ 2.1; 95% CI: 1.2-3.8). SF-36 scores are described in the table. Factors related to suboptimal PSS were surgery (OR ¼ 3.2, 95% CI: 2.0-5.1), low education (OR ¼ 1.9, 95% CI: 1.1-3.6) and number of comorbidities (OR ¼ 1.3, 95% CI: 1.0-1.5). No differences in PD or PSS were observed according to BC subtype. Conclusions: PD is very frequent during the initial stages of BC diagnosis and treatment. Advanced disease stage, lack of social support and low education are strong determinants of PD. The highest impact in HRQL was observed in the role-physical domain. PD and low PSS are interrelated and both are more frequent in patients with low education. Background: Neo-adjuvant (NA) chemotherapy (CT) þ/-anti-Her2 treatment of operable breast cancer (BC) is considered a standard option in the management of BC. However, pathologic complete response (pCR) rates with CT in hormonal receptorþ/ Her2 negative BC are usually low: 7% (Luminal A) to 16% (Luminal B). Alternatively, NA endocrine therapy (ET) has not been established as a standard treatment because of low pCRs (i.e. 5% using 8 months of ET). Trial design: This is a multicenter phase III, 3rd generation neo-adjuvant trial performed in 34 centers and 8 countries of Middle-East and Maghreb with the objective to investigate the potential role of the addition of a CDK 4/6 inhibitor (Palbociclib) to ET (Fulvestrantþ/-Goseriline) compared to ET alone as neo-adjuvant therapy of HRþ/ Her2-operable BC sensitive to ET. The question Is whether or not ET plus CDK 4/6 inhibitor would yield high enough pCR rates to establish this strategy as a reasonable therapeutic option in this group of patients (pts) with luminal HER2-BC. A total of 400 pts with stage II and IIIA are planned to be recruited in this trial. Oncotype DX will be performed upfront in order to eliminate CT candidates. All pre/peri and post-menopausal pts with a recurrence score < 31 will be treated with 4 months of Fulvestrant (500 mg Day (d.) 1, 14, 28 then q. 28 d. (þ/-Goseriline 3.6 mg q.28 d.). Patients with responding/stable disease will then be randomized in double blind fashion to Fulvestrant (þ/-Goseriline) either with Palbociclib 125mg po daily 3 weeks/4 or placebo. Four additional cycles will be delivered before surgery. The study primary endpoint is pCR while clinical/radiological response, rate of conservative surgery, safety, disease-free and overall survival are secondary endpoints. Exploratory endpoints encompass biomarker serial analysis of liquid biopsies with Quantum Optic and DNA methylation technologies. The SAFIA trial aims to identify a new neo-adjuvant standard with ET plus CDK 4/6 inhibitor in luminal -Her2 negative operable BC. Background: Given the increasing number of early-stage breast cancers detected by screening mammography, we aim to establish RFA as a minimally invasive, cost-efficient, and cosmetically acceptable local treatment. In our Phase I study, localized tumors with a maximum diameter of 2 cm, preoperatively diagnosed by imaging and histopathology, were treated with RFA. A 90% complete ablation rate was confirmed histopathologically. Trial design: The objective of our study is to demonstrate the non-inferiority of RFA compared with standard treatment in terms of local recurrence-free survival, which is the best index of local control. The inclusion criteria are untreated pts with histologically confirmed ductal carcinoma with a single localized tumor of 1.5 cm or less in the greatest dimension on preoperative imaging, no prior treatment for breast cancer. RFA is defined as a procedure in which a radiofrequency electrode needle is inserted into the breast lesion from the surface of the body under imaging guidance and thermal 
